Drugs /

[18f]f-arag

Back to Drugs List

Overview

NCI Definition [1]:
A radioconjugate composed of the guanosine analog arabinosyl guanine (Ara-G), a high-affinity substrate for both cytoplasmic deoxycytidine kinase (DCK) and mitochondrial deoxyguanosine kinase (dGK), labeled with fluorine F 18, that can potentially be used as a tracer for imaging of activated T-lymphocytes during positron emission tomography (PET). Upon administration, fluorine F 18 ara-G is taken up by and accumulates in activated T-lymphocytes with high levels of DCK and dGK. After phosphorylation by DCK and dGK, the 18F moiety can be visualized by PET imaging. Fluorine F 18 ara-G can potentially be used as an imaging agent to detect anti-tumor immune responses and to predict the therapeutic efficacy of immunotherapies. DCK and dGK, both nucleoside salvage pathway enzymes, are overexpressed in activated T-cells.

Clinical Trials

View Clinical Trials for [18f]f-arag

[18f]f-arag has been investigated in 2 clinical trials, of which 1 is open and 1 is closed. Of the trials investigating [18f]f-arag, 1 is phase 1 (1 open) and 1 is phase 2 (0 open).

Head and neck squamous cell carcinoma and non-small cell lung carcinoma are the most common diseases being investigated in [18f]f-arag clinical trials [2].

Drug Details

Synonyms [2]:
[18f] arag, [18f]f arag, 2'-deoxy-2'-[18f]fluoro-9-β-d-arabinofuranosylguanine, 2'-deoxy-2'-[18f]fluoro-9-beta-arabinofuranosylguanine, 2-deoxy-2-[18f]fluoro-9-beta-d-arabinofuranosylguanine, fluorine f 18 ara-g
NCIT ID [1]:
C120100

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.